You Position: Home > Paper
Anti-proliferation activity of celecoxib in cholangitis
( views:299, downloads:24 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 17
- DOI:
- 10.3969/j.issn.1009-3079.2010.17.004
- Key Word:
- 慢性增生性胆管炎;塞来昔布;肝内胆管结石
Abstract： 目的: 探讨塞来昔布在慢性增生性胆管炎(chronic proliferative cholangitis, CPC)治疗中的应用价值.方法: 健康♂SD大鼠30只, 随机分为3组: 假手术组( n = 10), CPC模型组( n = 10), 塞来昔布治疗组( n = 10). 模型组及治疗组经十二指肠乳头向胆总管逆行插入5-0尼龙缝合线, 直至肝门.假手术组仅开腹后关腹. 术后第1天开始治疗组予塞来昔布50 mg/(kg·d)腹腔注射. 1 wk后处死动物. 通过HE染色、Masson染色、PAS染色及免疫组织化学评估塞来昔布能否对CPC中过度增殖的胆管黏膜上皮、黏膜下腺体、胆管壁胶原纤维产生抑制作用及其效果.结果: 塞来昔布治疗组胆管黏膜上皮、黏膜下腺体、胆管壁胶原纤维的增殖较CPC模型组受到明显的抑制, 但略高于假手术组, 免疫组织化学示环氧化酶2(cyclooxygenase 2,COX-2)表达明显弱于CPC模型组(I A值: 8.62±0.19 vs 35.27±0.43, P<0.05), 与假手术组接近(I A值: 8.62±0.19 vs 8.41±0.13, P>0.05).结论: 塞来昔布可通过对COX-2的表达抑制,有效抑制胆管黏膜上皮、黏膜下腺体、管壁胶原纤维的过度增殖, 降低黏蛋白的高分泌,从而有望控制CPC, 降低肝内胆管结石术后复发率.
- [1]吴高松,刘正人,邹声泉,等.塞来昔布（celecoxib）通过前列腺素E2途径影响胆管癌细胞株生长和凋亡[J].2003,(2).
- [2]Ihab I El Hajj,Shahid M Malik,Hany R Alwakeel,etc.Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation[J].2009,(31).
- [3]巨邦律,方驰华.原发性肝内胆管结石的诊断和外科治疗[J].2004,(6).
- [4]黄志强.肝内胆管结石肝切除术的演变[J].2009,(1).
- [5]Yasuni Nakanuma,Kouji Yamaguchi,Goroku Ohta,etc.Pathologic features of hepatolithiasis in Japan[J].1988,19(10).
- [6]Bassignana,A.,Miglietta,A.,Lazzarato,L.,etc.Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth[J].2009,182(2).
- [7]陈燕凌.粘液糖蛋白成石作用的研究[J].1995,(3).
- [8]Chikao, Shimamoto,Shoko, Fujiwara,Masumi, Kato,etc.Inhibition of ACh-stimulated exocytosis by NSAIDs in guinea pig antral mucous cells: autocrine regulation of mucin secretion by PGE2.[J].2005,288(1).
- [9]Li FY,Cheng NS,Mao.Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.[J].2009,33(10).
- [10]Makdissi FF,Machado MA,Teixeira AR,etc.Laparoscopic right hemihepatectomy for hepatolithiasis.[J].2008,22(1).
- [11]Kompella UB,Amrite AC.Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism.[J].2008,324(2).
- [12]Atomi Y,Sugiyama M,Mori T.Gallstone disease: Management of intrahepatic stones.[J].2006,20(6).
- [13]陈燕凌,佘菲菲,黄建富,等.胆石病胆道感染不易廓清的原因[J].1996,(2).
- [14]Hatano Etsuro,Yoshida Masanori,Uehara Tetsuya,etc.Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.[J].2002,102(2).
- [15]P. Venkatesan,Soumen Das,M. Muthu Rama Krishnan,etc.Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques[J].2010,41(3).
- [16]Zhou H,Hu H,Tu Q,etc.Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis.[J].2010,46(6).
- [17]Tajima Y,Kuroki T,Kanematsu T.Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms.[J].2005,12(6).
- [18]Choi JY,Chung KC,Kim CH,etc.Prostaglandin E-2 induces MUC8 gene expression via a mechanism involving ERK MAPK/RSK1/cAMP response element binding protein activation in human airway epithelial cells[J].2005,280(8).
- [19]Jiang L,He S,Dong J,etc.The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis.[J].2005,127(2).
- [20]Cho YD,Cheon YK,Moon JH.Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis.[J].2009,146(5).
- [21]Cai X,Yu H,Wang Y,etc.Laparoscopic hepatectomy for hepatolithiasis: a feasibility and safety study in 29 patients.[J].2007,21(7).
- [22]R, Terao,K, Honda,E, Hatano,etc.Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract.[J].1998,28.
- [23]Jang LC,Lee SP,Park YH,etc.Suppression of proliferative cholangitis in a rat model by local delivery of paclitaxel.[J].2003,10(2).